Chakrabarti A, Verbridge S, Stroock AD, Fischbach C, Varner JD. Multiscale models of breast cancer progression. Ann Biomed Eng. 2012;40:2488–500.PubMed

Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett. 2013;341:80–96.PubMed

Grizzi F, Chiriva-Internati M. Cancer: looking for simplicity and finding complexity. Cancer Cell Int. 2006;6:4.PubMedCentralPubMed

Wang E, Zou J, Zaman N, Beitel LK, Trifiro M, Paliouras M. Cancer systems biology in the genome sequencing era: part 2. Evolutionary dynamics of tumor clonal networks and drug resistance. Semin Cancer Biol. 2013;23:286–92.PubMed

Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother. 2013;62:203–16.PubMedCentralPubMed

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.PubMed

Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates. Clin Epidemiol. 2012;4:1–11.PubMedCentralPubMed

Daly T, Hickey BE, Lehman M, Francis DP, See AM. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database Syst Rev. 2011(12):CD007234.

Moskovic DJ, Miles BJ, Lipshultz LI, Khera M. Emerging concepts in erectile preservation following radical prostatectomy: a guide for clinicians. Int J Impot Res. 2011;23:181–92.PubMed

Lawrentschuk N, Trottier G, Kuk C, Zlotta AR. Role of surgery in high-risk localized prostate cancer. Curr Oncol. 2010;17 Suppl 2:S25–32.PubMedCentralPubMed

Miyake H, Fujisawa M. Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches. Int J Urol. 2012;20:301–11.PubMed

Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, et al. Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg. 2012;67:270–5.PubMed

Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US preventive services task force review. J Clin Oncol. 2012;30:2581–4.PubMedCentralPubMed

Eylert MF, Persad R. Management of prostate cancer. Br J Hosp Med (Lond). 2012;73(2):95–9.

Spahn M, Haeni K. Approach to prostate cancer in men older than 75 years: active or passive? Urologe A. 2012;51:1368–74.PubMed

Kessler ER, Flaig TW. Optimal management of recurrent prostate cancer in older patients. Drugs Aging. 2012;29:871–83.PubMed

Albrand G, Mottet N, Ruffion A, Flechon A, Bensadoun RJ, Gigante M, et al. Prostate cancer in elderly subjects: how diagnosis should be made, why and how geriatric assessment should be implemented. Prog Urol. 2012;22 Suppl 2:S55–63.PubMed

Lee CH, Akin-Olugbade O, Kirschenbaum A. Overview of prostate anatomy, histology, and pathology. Endocrinol Metab Clin N Am. 2011;40:565–75.

Orsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2012;10:49–54.PubMed

Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 2009;133:1033–40.PubMed

Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559–65.PubMedCentralPubMed

Aschelter AM, Giacinti S, Caporello P, Marchetti P. Genomic and epigenomic alterations in prostate cancer. Front Endocrinol (Lausanne). 2012;3:128.

Holcomb IN, Young JM, Coleman IM, Salari K, Grove DI, Hsu L, et al. Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res. 2009;69:7793–802.PubMedCentralPubMed

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.PubMed

Nakagawa H, Akamatsu S, Takata R, Takahashi A, Kubo M, Nakamura Y. Prostate cancer genomics, biology, and risk assessment through genome-wide association studies. Cancer Sci. 2012;103:607–13.PubMed

Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA. Molecular pathology of prostate cancer. Cancer Biomark. 2010;9:441–59.PubMed

Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72:1248–61.PubMed

Richiardi L, Fiano V, Grasso C, Zugna D, Delsedime L, Gillio-Tos A, et al. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One. 2013;8:e68162.PubMedCentralPubMed

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–13.PubMedCentralPubMed

Barbieri CE, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology. 2012;60:187–98.PubMed

Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM. Staging of prostate cancer. Histopathology. 2012;60:87–117.PubMed

Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–37.PubMedCentralPubMed

Sun J, Turner A, Xu J, Gronberg H, Isaacs W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol. 2007;25:250–9.PubMed

Foye A, Febbo PG. Cancer gene profiling in prostate cancer. Methods Mol Biol. 2010;576:293–326.PubMed

Golias C, Charalabopoulos A, Stagikas D, Giannakopoulos X, Peschos D, Batistatou A, et al. Molecular profiling and genomic microarrays in prostate cancer. Exp Oncol. 2007;29:82–4.PubMed

Konishi N, Shimada K, Ishida E, Nakamura M. Molecular pathology of prostate cancer. Pathol Int. 2005;55:531–9.PubMed

Reynolds MA. Molecular alterations in prostate cancer. Cancer Lett. 2008;271:13–24.PubMed